赛托生物
(300583)
| 流通市值：27.16亿 | | | 总市值：27.68亿 |
| 流通股本：1.86亿 | | | 总股本：1.90亿 |
| 报告期 | 2025-06-30 | 2025-03-31 | 2024-12-31 | 2024-09-30 |
| 公司类型 | 通用 | 通用 | 通用 | 通用 |
| 一、营业总收入 | 507,762,685.42 | 259,850,364.44 | 970,601,329.97 | 765,034,045.74 |
| 营业收入 | 507,762,685.42 | 259,850,364.44 | 970,601,329.97 | 765,034,045.74 |
| 二、营业总成本 | 543,997,518.64 | 285,808,740.98 | 1,025,141,490.76 | 744,755,228.96 |
| 营业成本 | 446,758,264.14 | 236,613,828.58 | 784,898,739.68 | 563,185,270.27 |
| 税金及附加 | 6,205,392.39 | 2,807,000.5 | 13,961,207.67 | 10,736,643.67 |
| 销售费用 | 5,742,915.21 | 2,346,104.69 | 15,182,898.36 | 12,355,834.63 |
| 管理费用 | 45,799,367.18 | 22,599,980.39 | 120,474,199.43 | 92,297,375.3 |
| 研发费用 | 22,455,004.72 | 10,449,182.96 | 58,379,409.91 | 41,391,541 |
| 财务费用 | 17,036,575 | 10,992,643.86 | 32,245,035.71 | 24,788,564.09 |
| 其中:利息费用 | 15,506,361.01 | 8,771,284.02 | 30,853,015.77 | 22,889,820.17 |
| 其中:利息收入 | 1,233,898.24 | 800,326.73 | 2,407,587.78 | 3,412,192.84 |
| 三、其他经营收益 | | | | |
| 加:投资收益 | 4,091,379.24 | 2,770,396.94 | 12,349,077.69 | 10,869,510.28 |
| 资产处置收益 | -162,577.53 | - | 63,568.85 | -285,934.89 |
| 资产减值损失(新) | -23,252,340.73 | -5,679,426.72 | -75,091,679.09 | -21,710,361.39 |
| 信用减值损失(新) | -4,740,822.13 | -2,525,264.58 | 484,583.74 | 2,327,445.5 |
| 其他收益 | 3,314,055.55 | 2,094,882.38 | 14,671,923.73 | 9,702,493.42 |
| 四、营业利润 | -56,985,138.82 | -29,297,788.52 | -102,062,685.87 | 21,181,969.7 |
| 加:营业外收入 | 9,406.99 | 4,210.01 | 472,365.65 | 126,774.48 |
| 减:营业外支出 | 533,322.95 | 460,579.35 | 1,158,551.79 | 574,653.15 |
| 五、利润总额 | -57,509,054.78 | -29,754,157.86 | -102,748,872.01 | 20,734,091.03 |
| 减:所得税费用 | 2,327,305.36 | 2,198,782.66 | -1,420,606.43 | 7,533,431.14 |
| 六、净利润 | -59,836,360.14 | -31,952,940.52 | -101,328,265.58 | 13,200,659.89 |
| (一)按经营持续性分类 | | | | |
| 持续经营净利润 | -59,836,360.14 | -31,952,940.52 | -101,328,265.58 | 13,200,659.89 |
| (二)按所有权归属分类 | | | | |
| 归属于母公司股东的净利润 | -52,687,137.35 | -27,508,507.98 | -88,766,731.73 | 14,715,312.32 |
| 少数股东损益 | -7,149,222.79 | -4,444,432.54 | -12,561,533.85 | -1,514,652.43 |
| 扣除非经常损益后的净利润 | -53,481,635.07 | -27,813,133.29 | -103,361,225.34 | 5,507,229.33 |
| 七、每股收益 | | | | |
| (一)基本每股收益 | -0.28 | -0.15 | -0.47 | 0.08 |
| (二)稀释每股收益 | -0.28 | -0.15 | -0.47 | 0.08 |
| 八、其他综合收益 | - | - | - | 1,097,419.76 |
| 归属于母公司股东的其他综合收益 | - | - | - | 1,097,419.76 |
| 九、综合收益总额 | -59,836,360.14 | -31,952,940.52 | -101,328,265.58 | 14,298,079.65 |
| 归属于母公司股东的综合收益总额 | -52,687,137.35 | -27,508,507.98 | -88,766,731.73 | 15,812,732.08 |
| 归属于少数股东的综合收益总额 | -7,149,222.79 | -4,444,432.54 | -12,561,533.85 | -1,514,652.43 |
| 公告日期 | 2025-08-26 | 2025-04-29 | 2025-04-29 | 2024-10-29 |
| 审计意见(境内) | | | 标准无保留意见 | |